Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Gobbles Up Micromet In $1.16 Billion BiTE

This article was originally published in The Pink Sheet Daily

Executive Summary

With the acquisition of Micromet, Amgen gains a Phase II asset for hard-to-treat hematologic malignancies and a promising antibody platform known as Bispecific T cell Engager (BiTE).

You may also be interested in...



Deal Watch: Amgen BiTEs Back Micromet-Developed Boehringer Antibody

Cancer immunotherapy biotech Leap, backed by HealthCare Ventures and Lilly, reverse-merges with Israel's Macrocure. Elite and SunGen will partner to develop generic versions of four drugs that posted $3bn in aggregate sales over a recent 12-month stretch.

Amgen Bispecific Antibody Blincyto Gets Green Light From Europe’s CHMP

The acute lymphoblastic leukemia therapy, already available in the US, was recommended for a conditional approval in Europe to speed early patient access.

Amgen’s Breakthrough Blincyto Clears FDA At Breakneck Pace, But With REMS Attached

The big biotech’s blinatumomab gains accelerated approval to treat a rare form of ALL. The breakthrough therapy does have a REMS on serious risks and administration concerns.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS073302

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel